La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Vertex Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Le PDG Vertex Pharmaceuticals' est Reshma Kewalramani, nommé en Apr2020, a un mandat de 4.33 ans. La rémunération annuelle totale est $ 20.59M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.035% des actions de la société, d'une valeur de $ 44.40M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 4.5 ans.
Informations clés
Reshma Kewalramani
Directeur général
US$20.6m
Rémunération totale
| Pourcentage du salaire du PDG | 7.3% |
| Durée du mandat du directeur général | 4.4yrs |
| Propriété du PDG | 0.04% |
| Durée moyenne d'occupation des postes de direction | 4.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.6yrs |
Mises à jour récentes de la gestion
Recent updates
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
Rémunération vs marché: La rémunération totale de Reshma ($USD 20.59M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Reshma a augmenté alors que l'entreprise n'est pas rentable.
PDG
Reshma Kewalramani (51 yo)
4.4yrs
Titularisation
US$20,594,441
Compensation
Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 15.2yrs | US$6.60m | 0.0040% $ 5.0m | |
| CEO, President & Director | 4.4yrs | US$20.59m | 0.035% $ 43.2m | |
| Executive VP & CFO | 5.4yrs | US$7.37m | 0.018% $ 22.4m | |
| Executive VP & COO | 3.2yrs | US$9.00m | 0.019% $ 23.7m | |
| Executive VP & Chief Scientific Officer | 9.7yrs | US$6.54m | 0.010% $ 12.3m | |
| Senior VP & Chief Accounting Officer | 3.3yrs | pas de données | 0.0029% $ 3.6m | |
| SVP and Chief Information & Data Officer | 5.7yrs | pas de données | pas de données | |
| Senior Vice President of Investor Relations | 2yrs | pas de données | pas de données | |
| Executive VP & Chief Legal Officer | 2yrs | pas de données | 0.0071% $ 8.7m | |
| Senior VP & Chief Communications Officer | 5.7yrs | pas de données | pas de données | |
| Senior VP & Chief Human Resources Officer | 7.1yrs | pas de données | pas de données | |
| Executive VP & Chief Patient and External Affairs Officer | 17.2yrs | US$6.20m | 0.023% $ 27.6m |
4.9yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Gestion expérimentée: L'équipe de direction de VRTX est considérée comme expérimentée (ancienneté moyenne 4.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 15.2yrs | US$6.60m | 0.0040% $ 5.0m | |
| CEO, President & Director | 4.6yrs | US$20.59m | 0.035% $ 43.2m | |
| Lead Independent Director | 26.7yrs | US$600.04k | 0.015% $ 19.0m | |
| Independent Director | 7.3yrs | US$537.63k | 0.0023% $ 2.8m | |
| Independent Director | 5.6yrs | US$559.79k | 0.0021% $ 2.5m | |
| Independent Director | 9.3yrs | US$550.31k | 0.0013% $ 1.6m | |
| Independent Director | less than a year | US$449.08k | pas de données | |
| Independent Director | 4.3yrs | US$553.11k | 0.00064% $ 784.2k | |
| Independent Director | 2.3yrs | US$544.66k | 0.00060% $ 735.2k | |
| Independent Director | less than a year | US$407.65k | pas de données | |
| Independent Director | less than a year | pas de données | pas de données |
4.6yrs
Durée moyenne de l'emploi
59yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de VRTX sont considérés comme expérimentés (ancienneté moyenne 4.5 ans).